Patent intelligence · US
US 2005233966
Methods for controlling angiogenesis and cell proliferation
Methods for controlling angiogenesis and cell proliferation
Patent details — US 2005233966
- Jurisdiction
- US
- Status
- expired
- Grant date
- Oct 20, 2005
- Expiration
- Oct 15, 2025
- Applicant
- CANYON PHARMACEUTICALS INC [US]
- CPC classes
- A61K 38/ 54 A I, A61K 38/ 58 A I, A61K/3858, A61K38/54
Quick answer
US 2005233966 (Methods for controlling angiogenesis and cell proliferation) is held by CANYON PHARMACEUTICALS INC [US]. Status: expired. Granted Oct 20, 2005. Expires Oct 15, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CANYON PHARMACEUTICALS INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 54 A I, A61K 38/ 58 A I, A61K/3858, A61K38/54, A61P/3500, A61P/4300
Frequently asked questions
What is US patent 2005233966?
US 2005233966 (Methods for controlling angiogenesis and cell proliferation) is held by CANYON PHARMACEUTICALS INC [US]. Status: expired. Granted Oct 20, 2005. Expires Oct 15, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2005233966?
CANYON PHARMACEUTICALS INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 2005233966 expire?
Our index shows an expiration date of Oct 15, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.